Karyopharm Therapeutics Inc. operates as a publicly traded commercial-stage pharmaceutical enterprise listed on the Nasdaq Global Select Market under the ticker symbol KPTI. Operating as a public corporation allows the organization to access institutional capital markets, issue secondary public offerings, and secure funding through private placements to support its ongoing research, clinical development pipelines, and commercialization activities for its oncology and rare disease therapeutics.